Bearing Point Capital LLC Makes New $421,000 Investment in Abbott Laboratories (NYSE:ABT)

Bearing Point Capital LLC acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 3,725 shares of the healthcare product maker's stock, valued at approximately $421,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Redwood Park Advisors LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Noble Wealth Management PBC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC increased its stake in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after purchasing an additional 105 shares during the period. WealthTrak Capital Management LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at approximately $28,000. Finally, Rialto Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $29,000. Institutional investors own 75.18% of the company's stock.

Insider Buying and Selling

In other news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares in the company, valued at $4,415,960.28. The trade was a 7.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the sale, the senior vice president now directly owns 31,970 shares in the company, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,278 shares of company stock worth $12,745,859 in the last three months. Insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Up 1.6 %

Shares of NYSE:ABT opened at $132.92 on Monday. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The stock has a market capitalization of $230.53 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 2.52 and a beta of 0.80. The stock has a fifty day simple moving average of $130.21 and a two-hundred day simple moving average of $122.99. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.78%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.61%.

Analysts Set New Price Targets

A number of research firms recently commented on ABT. StockNews.com lowered shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. The Goldman Sachs Group increased their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Wells Fargo & Company boosted their target price on Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. Finally, Jefferies Financial Group upped their price objective on shares of Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $142.59.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.